Masami Suzuki

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami et al. · ACS Medicinal Chemistry Letters · 2010 · 247 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma

Shinichi Yachida, Laura D. Wood, Masami Suzuki et al. · Cancer Cell · 2016 · 193 citations · Full text

Medicine, Genetics, Oncology +12

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer

Erina Takai, Yasushi Totoki, Hiromi Nakamura et al. · Scientific Reports · 2015 · 187 citations · Full text

Medicine, Molecular Genetics, Oncology +17

TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats

Yoshiyuki Tsujihata, Ryo Ito, Masami Suzuki et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 145 citations

Medicine, Endocrinology, Pharmacology +17

Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System

Shinichi Yachida, Yasushi Totoki, Michaël Noë et al. · Utrecht University Repository (Utrecht University) · 2022 · 116 citations · Full text

Medicine, Molecular Genetics, Oncology +17